Diabetic neuropathy (DN) is a type of neuropathic pain that is difficult to treat clinically. One-third of diabetic patients would have peripheral neuropathic pain, on the other hand, about 50% of diabetic patients have abnormal expressions in nerve conduction. It is a process of gradual and diffuse nerve damage, which involves other factors besides simple exposure to hyperglycemia. The pathogenesis of DN and its complications is complex and multifactorial. Mitogen-activated protein kinase (MAPK) is considered to be a key intracellular component that transduces the biochemical and metabolic changes caused by hyperglycemia. MAPK, interleukins-1b, 2, 6, and 8, tumor necrosis factor-alpha, and other chemokines lead to DN. Satellite glial cells (SGCs) in dorsal root ganglia are activated in rodent models of type I DN induced by streptozotocin (STZ) and suggest that SGCs may participate in the generation and maintenance of diabetic neuropathic pain.
Currently, the identification and management of those at elevated risk of developing DN and its complications remain fragmented and are not linked to construction management. We can reasonably infer that inflammation and oxidative stress play an important role in the development and progression of its complications.
The current Research Topic aims to cover promising, recent, and novel research trends in the field of diabetic neuropathy, including pathogenesis, prevention, diagnosis, and the latest approach for meeting the need for continuous individualization of the therapies. We invite researchers in the field to submit original research and review articles including (but not limited to) studies on the fine-tuning of treatments in diabetic neuropathy and its complications using objective, personalized, and precision medicine, pharmacogenomics, bioinformatics, integrative computational approaches, and clinical biomarker discovery.
Areas to be covered in this Research Topic may include, but are not limited to:
• Recent developments in diabetic neuropathy research, especially identifying potential biomarkers/correlates of inflammation on blood-nerve barrier.
• Latest technologies for clinical evaluation and measuring outcomes, especially neural inflammation in neuroimage findings
• New cellular and animal models to test and understand diabetic neuropathy
• Therapeutic strategies (e.g., pharmacogenomics)
• Advanced bioinformatics, integrative computational approaches techniques
Diabetic neuropathy (DN) is a type of neuropathic pain that is difficult to treat clinically. One-third of diabetic patients would have peripheral neuropathic pain, on the other hand, about 50% of diabetic patients have abnormal expressions in nerve conduction. It is a process of gradual and diffuse nerve damage, which involves other factors besides simple exposure to hyperglycemia. The pathogenesis of DN and its complications is complex and multifactorial. Mitogen-activated protein kinase (MAPK) is considered to be a key intracellular component that transduces the biochemical and metabolic changes caused by hyperglycemia. MAPK, interleukins-1b, 2, 6, and 8, tumor necrosis factor-alpha, and other chemokines lead to DN. Satellite glial cells (SGCs) in dorsal root ganglia are activated in rodent models of type I DN induced by streptozotocin (STZ) and suggest that SGCs may participate in the generation and maintenance of diabetic neuropathic pain.
Currently, the identification and management of those at elevated risk of developing DN and its complications remain fragmented and are not linked to construction management. We can reasonably infer that inflammation and oxidative stress play an important role in the development and progression of its complications.
The current Research Topic aims to cover promising, recent, and novel research trends in the field of diabetic neuropathy, including pathogenesis, prevention, diagnosis, and the latest approach for meeting the need for continuous individualization of the therapies. We invite researchers in the field to submit original research and review articles including (but not limited to) studies on the fine-tuning of treatments in diabetic neuropathy and its complications using objective, personalized, and precision medicine, pharmacogenomics, bioinformatics, integrative computational approaches, and clinical biomarker discovery.
Areas to be covered in this Research Topic may include, but are not limited to:
• Recent developments in diabetic neuropathy research, especially identifying potential biomarkers/correlates of inflammation on blood-nerve barrier.
• Latest technologies for clinical evaluation and measuring outcomes, especially neural inflammation in neuroimage findings
• New cellular and animal models to test and understand diabetic neuropathy
• Therapeutic strategies (e.g., pharmacogenomics)
• Advanced bioinformatics, integrative computational approaches techniques
